D-chiro-inositol negatively regulates the formation of multinucleated osteoclasts by down-regulating NFATc1

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1360-1371

  Yu, Jungeun ^a   Choi, Seunga ^a   Park, Eui Soon ^a   Shin, Bongjin ^a   Yu, Jiyeon ^a   Lee, Seoung Hoon ^b   Takami, Masamichi ^c   Kang, Jong Soon ^d   Meong, Hyungun ^e   Rho, Jaerang ^a  

^a Chungnam National University   (South Korea)

^b Wonkwang University   (South Korea)

^c SHOWA UNIVERSITY   (Japan)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Solgent Co Ltd   (South Korea)

Author keywords

D chiro inositol; NFATc1; osteoclast differentiation; RANKL

Indexed keywords

3 O METHYL DEXTRO CHIRO INOSITOL; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIINFLAMMATORY AGENT; CELL MARKER; CELL PROTEIN; DEXTRO CHIRO INOSITOL; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN NFATC1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DRUG DERIVATIVE; INOSITOL; NFATC1 PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL FUSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME PURIFICATION; GENE EXPRESSION; GENETIC MARKER; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENETICS; GIANT CELL; HUMAN; METABOLISM; PATHOLOGY; STEREOISOMERISM;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL FUSION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION; GIANT CELLS; HUMANS; INOSITOL; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; STEREOISOMERISM;

EID: 84878242135     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9722-z     Document Type: Article

References (42)

1. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells. 2004;17(1):1-9.
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev. 2007;7(4):292-304.
3. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33-63.
4. Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998;19(1):18-54.
5. Inaba M. Secondary osteoporosis: thyrotoxicosis, rheumatoid arthritis, and diabetes mellitus. J Bone Miner Metab. 2004;22(4):287-92.
6. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22(9):1317-28.
7. Rakel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 2008;34(3):193-205.
8. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8(4):178-84.
9. Vestergaard P. Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes. 2009;16(2):125-31.
10. Davis A, Christiansen M, Horowitz JF, Klein S, Hellerstein MK, Ostlund Jr RE. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000;23(7):1000-5.
11. Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA. 1993;90(13):5924-8.
12. Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol. 2000;130(8):1944-8.
13. Dang NT, Mukai R, Yoshida K, Ashida H. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem. 2010;74(5):1062-7.
14. Geethan PK, Prince PS. Antihyperlipidemic effect of D-pinitol on streptozotocin-induced diabetic Wistar rats. J Biochem Mol Toxicol. 2008;22(4):220-4.
15. Kim JI, Kim JC, Kang MJ, Lee MS, Kim JJ, Cha IJ. Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr. 2005;59(3):456-8.
16. Sivakumar S, Palsamy P, Subramanian SP. Attenuation of oxidative stress and alteration of hepatic tissue ultrastructure by D-pinitol in streptozotocin-induced diabetic rats. Free Radic Res. 2010;44(6):668-78.
17. Bhat KA, Shah BA, Gupta KK, Pandey A, Bani S, Taneja SC. Semi-synthetic analogs of pinitol as potential inhibitors of TNF-alpha cytokine expression in human neutrophils. Bioorg Med Chem Lett. 2009;19(7):1939-43.
18. Lee JS, Lee CM, Jeong YI, Jung ID, Kim BH, Seong EY, et al. D-pinitol regulates Th1/Th2 balance via suppressing Th2 immune response in ovalbumin-induced asthma. FEBS Lett. 2007;581(1):57-64.
19. Sethi G, Ahn KS, Sung B, Aggarwal BB. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther. 2008;7(6):1604-14.
20. Sivakumar S, Palsamy P, Subramanian SP. Impact of D-pinitol on the attenuation of proinflammatory cytokines, hyperglycemia-mediated oxidative stress and protection of kidney tissue ultrastructure in streptozotocin-induced diabetic rats. Chem Biol Interact. 2010;188(1):237-45.
21. Lee SH, Kim T, Park ES, Yang S, Jeong D, Choi Y, et al. NHE10, an osteoclast-specific member of the Na+/H+ exchanger family, regulates osteoclast differentiation and survival [corrected]. Biochem Biophys Res Commun. 2008;369(2):320-6.
22. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nature Medicine. 2006;12(12):1403-9.
23. Kindt E, Shum Y, Badura L, Snyder PJ, Brant A, Fountain S, et al. Development and validation of an LC/MS/MS procedure for the quantification of endogenous myo-inositol concentrations in rat brain tissue homogenates. Anal Chem. 2004;76(16):4901-8.
24. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nature Medicine. 2009;15(9):1066-71.
25. Courtial N, Smink JJ, Kuvardina ON, Leutz A, Gothert JR, Lausen J. Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP. FASEB J. 2012;26(2):523-32.
26. Smink JJ, Begay V, Schoenmaker T, Sterneck E, de Vries TJ, Leutz A. Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB. EMBO J. 2009;28(12):1769-81.
27. Pak Y, Hong Y, Kim S, Piccariello T, Farese RV, Larner J. In vivo chiro-inositol metabolism in the rat: a defect in chiro-inositol synthesis from myo-inositol and an increased incorporation of chiro-[3H]inositol into phospholipid in the Goto-Kakizaki (G.K) rat. Mol Cells. 1998;8(3):301-9.
28. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293(3):1092-8.
29. Choi MS, Lee WH, Kwon EY, Kang MA, Lee MK, Park YB, et al. Effects of soy pinitol on the pro-inflammatory cytokines and scavenger receptors in oxidized low-density lipoprotein-treated THP-1 macrophages. J Med Food. 2007;10(4):594-601.
30. Do GM, Choi MS, Kim HJ, Woo MN, Lee MK, Jeon SM. Soy pinitol acts partly as an insulin sensitizer or insulin mediator in 3T3-L1 preadipocytes. Genes Nutr. 2008;2(4):359-64.
31. Ostlund Jr RE, Seemayer R, Gupta S, Kimmel R, Ostlund EL, Sherman WR. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. J Biol Chem. 1996;271(17):10073-8.
32. Yoshino K, Takeda N, Sugimoto M, Nakashima K, Okumura S, Hattori J, et al. Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats. Metabolism. 1999;48(11):1418-23.
33. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997;11(24):3482-96.
34. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997;3(11):1285-9.
35. Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res. 2005;20(4):653-62.
36. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res. 2002;17(7):1200-10.
37. Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231(1):241-56.
38. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261-9.
39. Lee JS, Jung ID, Jeong YI, Lee CM, Shin YK, Lee SY, et al. D-pinitol inhibits Th1 polarization via the suppression of dendritic cells. Int Immunopharmacol. 2007;7(6):791-804.
40. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-64.
41. Liu SC, Chuang SM, Tang CH. d-pinitol inhibits RANKL-induced osteoclastogenesis. Int Immunopharmacol. 2012;12(3):494-500.
42. Ang ES, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, et al. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. J Cell Physiol. 2009;221(3):642-9.